Corvus Pharmaceuticals, Inc. (CRVS)
10.17
-0.43
(-4.06%)
USD |
NASDAQ |
Nov 17, 16:00
10.50
+0.33
(+3.24%)
After-Hours: 20:00
Corvus Pharmaceuticals Total Assets (Quarterly) : 223.88M for Sept. 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 223.88M |
| June 30, 2026 | 239.27M |
| March 31, 2026 | 253.20M |
| December 31, 2025 | 71.12M |
| September 30, 2025 | 80.47M |
| June 30, 2025 | 89.46M |
| March 31, 2025 | 59.44M |
| December 31, 2024 | 68.91M |
| September 30, 2024 | 58.82M |
| June 30, 2024 | 64.56M |
| March 31, 2024 | 40.08M |
| December 31, 2023 | 45.55M |
| September 30, 2023 | 51.94M |
| June 30, 2023 | 58.04M |
| March 31, 2023 | 58.20M |
| December 31, 2022 | 68.24M |
| September 30, 2022 | 80.35M |
| June 30, 2022 | 92.54M |
| March 31, 2022 | 101.29M |
| December 31, 2021 | 109.46M |
| September 30, 2021 | 119.32M |
| June 30, 2021 | 109.39M |
| Date | Value |
|---|---|
| March 31, 2021 | 109.24M |
| December 31, 2020 | 85.53M |
| September 30, 2020 | 55.86M |
| June 30, 2020 | 64.18M |
| March 31, 2020 | 73.80M |
| December 31, 2019 | 83.65M |
| September 30, 2019 | 92.47M |
| June 30, 2019 | 103.12M |
| March 31, 2019 | 112.31M |
| December 31, 2018 | 118.23M |
| September 30, 2018 | 127.22M |
| June 30, 2018 | 137.92M |
| March 31, 2018 | 148.69M |
| December 31, 2017 | 94.78M |
| September 30, 2017 | 104.79M |
| June 30, 2017 | 115.49M |
| March 31, 2017 | 127.10M |
| December 31, 2016 | 140.15M |
| September 30, 2016 | 149.76M |
| June 30, 2016 | 156.92M |
| March 31, 2016 | 157.22M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arcturus Therapeutics Holdings, Inc. | 215.32M |
| CytomX Therapeutics, Inc. | 364.68M |
| ACADIA Pharmaceuticals, Inc. | 1.794B |
| Alnylam Pharmaceuticals, Inc. | 7.995B |
| Anika Therapeutics, Inc. | 189.60M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 15.56M |
| Shareholders Equity (Quarterly) | 208.32M |
| Debt to Equity Ratio | 0.003 |
| Current Ratio | 13.38 |
| Net Debt Paydown Yield | 0.01% |